Morgan Stanley Upgrades Rhythm Pharmaceuticals to Overweight, Raises Price Target to $55
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Jeffrey Hung upgraded Rhythm Pharmaceuticals (NASDAQ:RYTM) from Equal-Weight to Overweight and increased the price target from $29 to $55.
December 19, 2023 | 2:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Rhythm Pharmaceuticals' stock rating was upgraded by Morgan Stanley from Equal-Weight to Overweight, with a significant price target increase from $29 to $55.
Analyst upgrades typically lead to positive market sentiment in the short term, especially when accompanied by a substantial price target increase. The upgrade from Equal-Weight to Overweight suggests a strong bullish outlook on RYTM by Morgan Stanley, which could lead to increased investor interest and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100